Lesinurad (brand name Zurampic) is a urate transporter inhibitor for treating high blood uric acid levels associated with gout.

[4] In February 2019, lesinurad was discontinued in the United States by its manufacturer for business reasons, and was subsequently withdrawn in Europe in July 2020.

[5][6] Lesinurad is used in combination with a xanthine oxidase inhibitor, such as allopurinol or febuxostat, for treating hyperuricemia (high levels of uric acid in the blood serum) associated with gout.

It is approved only for patients who have not achieved target uric acid levels with a xanthine oxidase inhibitor alone.

[7][8] In clinical trials, serum creatinine (an important marker for kidney function) was elevated in 4.3 to 7.8% of patients depending on the dose, as compared to 2.3% under placebo.

Some drugs that are metabolized by this enzyme have been shown to be slightly less effective when combined with lesinurad, examples including simvastatin and warfarin.

On the other hand, lesinurad concentrations in the blood are decreased by drugs that induce CYP2C9 and increased by substances that inhibit this enzyme (such as fluconazole), as well as in people who have genetically determined low CYP2C9 activity.